Biomarker study of Atezolizumab plus Bevacizumab for PD-L1 High Non-Sq NSCLC
Not Applicable
Completed
- Conditions
- non-small-cell lung cancer
- Registration Number
- JPRN-jRCT1080224072
- Lead Sponsor
- Kaname Nosaki (Principal Investigator)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
1. Patient enrolled into WJOG10718L (A Phase II Study of Atezolizumab with Bevacizumab for Patients with PD-L1 High Expression Non-Small Cell Non-Squamous Cell Lung Cancer)
2. Written informed consent to biomarker study
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety<br>efficacy<br>The correlation between immunological biomarker and the efficacy and safety in WJOG10718L<br>Retrospective analysis to explore the immunological biomarkers (bTMB /LC-SCRUM-IBIS /LC-SCRUM-Liquid) related to the efficacy and safety in WJOG10718L will be performed
- Secondary Outcome Measures
Name Time Method other<br>-